 | Up a level |
Journal Article
Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C. M., Chagorova, T., Dela Serna, J., Dilhuydy, M. S., Opat, S., Owen, C. J., Samoylova, O., Kreuzer, K. A., Langerak, A. W., Ritgen, M., Stilgenbauer, S., Doehner, H., Asikanius, E., Humphrey, K., Wenger, M. K. and Hallek, M. (2014). Obinutuzumab (GA101) plus chlorambucil (Clb) versus rituximab plus Clb in patients with chronic lymphocytic leukaemia (CLL) and comorbidities: recently published results of the CLL11 trial. Br. J. Haematol., 165. S. 19 - 20. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141
Goede, V., Fischer, K., Engelke, A., Schlag, R., Lepretre, S., Montero, L. F. C., Montillo, M., Fegan, C., Asikanius, E., Humphrey, K., Fingerle-Rowson, G. and Hallek, M. (2015). Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia, 29 (7). S. 1602 - 1606. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551